Regeneron Pharmaceuticals (REGN) Current Deferred Tax Assets (2012 - 2015)

Regeneron Pharmaceuticals' Current Deferred Tax Assets history runs 4 years deep, the most recent figure standing at $60.5 million for Q3 2015.

• On a quarterly basis, Current Deferred Tax Assets rose 23.5% year-over-year to $60.5 million in Q3 2015; TTM through Sep 2015 was $60.5 million, a 23.5% increase from a year earlier, with the FY2014 full-year figure at $46.2 million, up 3.36% from the prior year.
• Current Deferred Tax Assets declined to $60.5 million in Q3 2015 per REGN's latest filing, from $69.6 million in the prior quarter.
• Across five years, Current Deferred Tax Assets topped out at $148.1 million in Q4 2012 and bottomed at $36.6 million in Q1 2014.
• The 4-year median for Current Deferred Tax Assets is $47.6 million (2014), against an average of $61.0 million.
• Across the five-year window, Current Deferred Tax Assets sank 69.84% in 2013 and soared 86.65% in 2015, its largest moves.
• Year by year, Current Deferred Tax Assets stood at $148.1 million in 2012, then tumbled by 69.84% to $44.7 million in 2013, then gained by 3.36% to $46.2 million in 2014, then soared by 31.06% to $60.5 million in 2015.
• Per Business Quant, the three latest REGN Current Deferred Tax Assets figures stand at $60.5 million (Q3 2015), $69.6 million (Q2 2015), and $62.1 million (Q1 2015).